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by Stephen Senn
Three things that every 
medical writer should know 
about statistics
Introduction
The joke goes that there are three kind of statistician: those 
who can count and those who can’t. Therefore, readers of 
the Write Stuff will forgive me, I hope, if I end up writ-
ing about more than three things. It should be obvious, in 
that case, as to which sort of statistician I am. There are, 
of course, many more things than three that every medi-
cal writer should know about statistics because there are 
many things about statistics that anybody working in drug 
development should know and medical writers are in the 
unenviable position of having to know about everything. 
However, everybody has to start somewhere and three is a 
number with a great tradition. The three things I am going 
to write about are regression to the mean [1], the error of 
the transposed conditional [2] and individual response [3]. 
The first is a widespread phenomenon that has a powerful 
influence on the way that results appear to us, the second 
is a pernicious fallacy and the third is a sort of Holy Grail-
cum-wild goose chase that is responsible for leading many 
a researcher astray.
Regression to the mean
Regression to the mean is the tendency for members of a 
population who have been selected because they are ex-
treme to be less extreme when measured again [4, 5]. Be-
cause entry into clinical trials is usually only allowed if pa-
tients have extreme values (diastolic blood pressure above 
95 mmHg, Hamilton depression score greater than or equal 
to 22, forced expiratory volume in one second less than 
75% of predicted etc.), regression to the mean is a phe-
nomenon that is likely to affect many clinical trials. We can 
expect that patients will appear to improve even if the treat-
ment is ineffective. Regression to the mean is a plausible 
explanation, for example, for the ‘placebo effect’ which 
then becomes, as I hope to explain, a purely statistical rath-
er than psychological phenomenon.
How does it occur? Consider figure 1. This shows a simu-
lated set of results for a group of 1000 individuals who have 
had their diastolic blood pressure (DBP) measured on two 
occasions: at ‘baseline’, X, and at ‘outcome’, Y. The figure 
plots Y against X and the simulation has been arranged so 
that the expected values of X and Y are identically equal 
to 90 mmHg and that the standard deviations are 8 mmHg 
with a correlation of 0.79. An arbitrary but common cut off 
of 95 mmHg is taken as being the boundary for hyperten-
sion. Individuals are labelled as being of one of three sorts: 
hypertensive at both baseline and outcome (labelled with 
a red +), normotensive at both baseline and outcome (la-
belled with a blue 0) and hypertensive on one occasion and 
not the other (labelled with an orange x).
Figure 1 Simulated results at baseline and outcome for diastolic blood pres-
sure (mmHg) for 1000 individuals in a population.
Now consider a plot of a subset of the individuals, namely 
those who are ‘hypertensive’ on at least one occasion. This 
plot is given in figure 2. Just as was the case in figure 1 
there is no essential difference as to whether we look at 
results at baseline or outcome, the mean result on either 
occasion, although higher than it was before because the 
‘normotensives’ have been removed, will be the same.
Figure 2 Simulated results at baseline and outcome for diastolic blood pres-
sure (mmHg) for 1000 individuals in a population with those who 
are normotensive on both occasions removed.
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However, neither of these plots is what we would observe 
in a standard clinical trial. Instead, we would observe some-
thing like figure 3. Figure 3 has been obtained from figure 
2 by removing those patients who were normotensive at 
baseline but hypertensive at outcome. Why? Because if 
they were normotensive at baseline they would never be 
recruited into the trial and hence never followed up. Now 
we can see that the way that we have chosen subjects has 
an inherent bias if we measure the effect of treatment as 
the difference between outcome and baseline. The outcome 
values are on average lower than the baseline values but 
this is only because of the way that we have sampled. It 
says nothing about the effect of treatment.
Figure 3 Simulated results at baseline and outcome for diastolic blood pres-
sure (mmHg) for 1000 individuals in a population with those who 
are normotensive at baseline removed.
The consequence is that on average patients will appear to 
improve even if the treatment is ineffective. In fact, patients 
given placebo can be expected to improve for reasons that 
are purely statistical. There is no need to invoke psycholo-
gy, the healing hands of the physician, the white coat effect 
and so forth. The way that the data are collected suffices.
Does it matter? Not in a controlled clinical trial provided 
that we only consider, describe and interpret differences be-
tween treatment and control groups. Both of these will be 
subject to the same regression to the mean effect, which is 
therefore eliminated by comparison. Hence, the joke about 
a medical statistician. If you ask him, “how’s your wife?” 
he answers, “compared to what?” Only head to head com-
parisons have meaning. Alas, many clinical trial reports re-
veal that trialists have no idea why they have carried out a 
controlled clinical trial. Pages of ink are wasted describing 
the response in each group, although this is meaningless. 
Reports would be sharper and understanding would be im-
proved if these ignorant descriptions were dumped where 
they belong in the waste paper basket.
What are the lessons for a medical writer? He or she should 
think comparatively. Controlled clinical trials are about 
comparisons, or to use some statistical jargon treatment 
contrasts, that is to say difference between treatments. Giv-
en a choice between a graph that shows the course over 
time of each treatment together with standard error bars or 
a plot of the difference between treatments together with 
confidence interval for that difference, choose the latter and 
dump the former. If survival is the outcome of interest, it is 
the log-hazard ratio, a statistic used to model the difference 
between treatments, that should take pride of place and not 
the median survival within each group. For a binary out-
come, stress the odds ratio rather than the probability for 
each group.
The error of the transposed conditional
All French are Europeans but not all Europeans are French. 
I can put this in the language of probabilities. With a proba-
bility of 100% someone who is French is European. Howev-
er, the probability that a randomly chosen European (taking 
this to mean a citizen of the European Union) is French is 
only about 13% (since the population of France is about 65 
million and that of the European Union about 500 million). 
Here is another example. The probability that a randomly 
chosen woman has breast cancer is, thank goodness, quite 
low. However the probability that a randomly chosen breast 
cancer victim is a woman is extremely high. Or how about 
the prosecutor’s fallacy? The probability of the DNA on 
the scene of the crime matching that of the defendant is 
one in a million, therefore, claims the prosecution, there are 
999,999 chances out of a million that he is guilty. However, 
in a population of 100 million (which could be the number 
of adult males in the USA) there must be 100 individuals 
about whom we could make a similar statement. They can’t 
all be almost certainly guilty.
This is all very obvious and 
elementary, yet, surprising-
ly, even experienced trialists 
find it hard to grasp that the 
probability of A given B is 
not the same as the probabil-
ity of B given A. Consider 
that most ubiquitous of statistics, the P-value. A P-value 
is the probability of seeing a result as extreme or more ex-
treme than that observed if the null hypothesis is true. In 
other words it says something about the probability of the 
evidence given the null hypothesis. It is not, therefore, the 
probability of the hypothesis given the evidence. Yet it is 
often misinterpreted as being the probability that the null 
hypothesis is true. This is just an egregious error.
P-values are a concept in frequentist statistics. The frequen-
tist approach to statistics is the approach generally used in 
drug development. In this approach it is never possible 
to talk of the probability of a hypothesis being true. The 
hypothesis is either true or false. The problem is we don’t 
know which. If one wished to make statements about the 
truth of a hypothesis one would have to use the Bayesian 
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system of inference but, in fact, this is rarely employed in 
a regulatory context.
What are the lessons for medical writers? Be careful in re-
phrasing statistical statements. Here there be tygers! You 
may find the way that statisticians formulate probabilistic 
statements clumsy. However, you simplify at your peril. Un-
fortunately, many prefer a simple lie to a complicated truth 
but being truthful is what reporting clinical trials is all about.
Individual response
Despite a gross of ‘points to consider’ documents to the 
contrary, individual response is usually not identifiable in 
a clinical trial. By that I mean that it is usually not possible 
to say who has and who has not responded to treatment in 
a clinical trial. I shall make good this claim in due course 
but cannot resist pointing out that many in drug develop-
ment, including, if the published record is anything to go 
by, most of the European regulators, are deeply confused 
on this issue.
Consider a thought experiment in which we run two pla-
cebo-controlled cross-over trials in hypertension in succes-
sion. In each cross-over trial we will be able to compare 
the DBP under treatment and placebo. We will thus be able 
to construct two estimates for every patient of the effect 
of treatment compared to placebo using the difference be-
tween active treatment and placebo: one for each of the two 
cross-over trials. What pattern might we expect from such 
an experiment?
Figures 4 and 5 show two very different patterns. What 
these figures plot is the ‘response’ patient by patient for 
the second cross-over trial compared to the first. In fact 
these are based on a simulation in which I set the differ-
ence between treatment and placebo in DBP to be on aver-
age 10 mmHg. That is to say I set it to be 10 mmHg lower 
on average under treatment. Solid lines at –10 mmHg indi-
cate the centres of the distributions. Also shown are dashed 
lines at –5 mmHg corresponding to an arbitrary definition 
of response whereby any patient who shows a 5 mmHg im-
provement compared to placebo is labelled a ‘responder’.
Figure 4 Patients cross-classified by difference in DBP (mmHg) treatment minus 
placebo for two successive cross-over trials. Case of strong correlation.
What the figures show right away is that this sort of ar-
bitrary label is very silly. A great deal of information is 
lost by turning a continuous scale into a binary one and 
the boundary is, of course, arbitrary. What the figures also 
show, however, is that one has to be very careful as to how 
one interprets ‘response’.
Figure 5 Patients cross-classified by difference in DBP (mmHg) treatment minus 
placebo for two successive cross-over trials. Case of no correlation.
In the case of figure 4, there is a strong correlation between 
the degree of response in the first cross-over and the degree 
of response in the second. It thus becomes meaningful to 
think of response as being a feature of the patient. There 
seem to be some patients who respond well to the anti-
hypertensive agent—these are those shown as blue circles. 
There are also some who respond less well and, using our 
standard of –5mmHg, these are shown as red crosses. Very 
few patients show an inconsistent pattern.
However, in figure 5 the situation is quite different. Here 
‘response’ in the first cross-over does not appear to predict 
response in the second. This can be shown by producing 
the following table (see table 1) of cross-classified results. 
Of the 826 patients who responded in the first cross-over 
678 responded in the second. The proportion, therefore is 
678/826=0.82. However of the 174 who did not respond in 
the first, 140 responded in the second. The proportion, there-
fore, is 140/174 =0.80. This is almost identical to the previ-
ous figure. It thus seems that at any time any patient has 
about four chances out of five of responding and about one 
chance out of five of not responding. It thus becomes mean-
ingless to think in terms of responders and non-responders.
Table 1 Patients cross-classified by response in two cross-over trials
Count
Second cross-over responder non-responder Count
First cross-over  
responder 678 148 826
nonresponder 140 34 174
Count 818 182 1000
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Also, included in figures 4 and 5 are some histograms 
showing the marginal distributions of ‘response’. Now 
suppose that, in fact, we had never run the second cross-
over trial. All that we would have to go on would be the 
marginal figures, summarised by the histograms given on 
the X axis of figures 4 and 5. The point is, however, that 
from these marginal histograms it is impossible to predict 
whether we would see something like figure 4 or figure 5 in 
carrying out a second cross-over trial.
In other words, a single 
cross-over trial is inadequate 
for distinguishing responders 
from non-responders. What 
applies to cross-over trials 
applies a fortiori to parallel group 
trials. It is a fact of drug de-
velopment that we simply do 
not run the sort of trial that 
would allow us to separate re-
sponders from non-respond-
ers and much of the hype about pharmacogenomics is based 
on the largely untested hypothesis that patients respond very 
differently to treatment from each other [6].
What are the lessons for medical writers? The less ink you 
waste in any clinical trial discussing individual ‘response’ 
the better. What most clinical trials deliver are averages. 
That’s all. A placebo-controlled parallel group trial in hy-
pertension will tell you what the average difference com-
pared to placebo in DBP is due to taking treatment. That’s 
it. Anything else is unscientific speculation.
Categorising patients as responders and non-responders by 
comparing their values to baseline does not control for re-
gression to the mean, does not establish that patients can be 
so-classified in any meaningful way, is in any case arbitrary 
and is inefficient. (An analysis of responders rather than in 
terms of a continuous measurement such as DBP will lead 
to a large increase in the sample size needed.)
In conclusion
I finish by giving a list of recommendations
1. Be aware of regression to the mean. The way that data 
are collected in clinical trials means that comparison to 
baseline is inherently misleading.
2. Think comparatively. Randomised clinical trials are 
valuable because they provide concurrent control and 
thus eliminate many biases. This elimination is only 
achieved, however, by actually taking the last step and 
making the head to head comparison. The difference 
between treatment and control is what the clinical trial 
is about. The rest is unimportant.
3. Be careful with probability. Be on your guard for over-
simplifications. Do not confuse the probability of A giv-
en B with that of B given A.
4. Watch out for the weasel word response. Use it spar-
ingly. It takes hundreds and sometimes thousands of 
patients to show that a treatment works at all. It is usu-
ally impossible to tell in any individual case whether a 
patient has or has not benefitted.
Finally, I should like to recommend a book I rather like. In 
fact, I wrote it myself. It’s called Dicing with Death [7]. If you 
find that this article challenged your intuition and if you are 
not afraid of being challenged, you might find it interesting. 
Stephen Senn
Department of Statistics, 
University of Glasgow, 
Glasgow, UK
stephen@stats.gla.ac.uk
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The sequel: JAMA and 
conflicts of interest
A box in the last issue of TWS (18(2):143) reported 
that The Journal of the American Medical Association 
(JAMA) had changed its policies on investigations of 
conflicts of interest to require whistleblowers to wait un-
til JAMA had completed its investigations (however long 
these might take) before going public on their complaint. 
This policy and the events surrounding Jonathan Leo’s 
complaint and JAMA’s reaction resulted in heavy of criti-
cism JAMA. The editors had published the new policies 
in an editorial on its website [1]. The next event was that 
the editorial disappeared from the website and all bio-
medical databases. This raised questions in the medical 
editors’ community about the ethics of erasing the publi-
cation record. Udo Schuklenk pointed out on the WAME 
listserver that according to information he had received 
from Wiley-Blackwell anything published with a DOI 
number online must not be changed in any print version 
or on-line without a notice of retraction or erratum be-
cause an on-line paper with a doi number is treated just 
like a print article [2]. JAMA did not publish any such no-
tice or erratum. A new milder version of the editorial was 
published in the 8th July issue of JAMA [3]. The Ameri-
can Medical Association’s board of trustees are report-
ed to have examined concerns raised over how JAMA’s 
editors had handled the issue. Rebecca Patchin, who is 
the chairwoman of the association, stated, “We anticipate 
JAMA’s procedures for resolving undisclosed conflicts of 
interest by journal authors will be improved” [4].
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